SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adaptimmune Therapeutics plc - ADAP

September 17, 2022 8:44 PM EDT | Source: Pomerantz LLP

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc ("Adaptimmune" or the "Company") (NASDAQ: ADAP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Adaptimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 9, 2022, Adaptimmune issued a press release announcing new data from its Phase 1 SURPASS trial for anti-cancer agent ADP-A2M4CD8 in patients with solid tumors. Among other results, the press release disclosed that "[a]mong adverse events (AEs) of special interest: 32 people (73%) had cytokine release syndrome (CRS); most events were low grade and resolved (~86% ≤ Grade 2). Eleven people (25%) had cytopenia (Grade ≥3) at 4 weeks after treatment. Three people (7%) had Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) related to ADP-A2M4CD8." The press release also stated that "[t]here were 2 deaths reported as related to ADP-A2M4CD8 by investigators. A 60-year-old woman with ovarian cancer with a large tumor burden in her lungs died due to pneumonia and CRS" and "a 71-year-old man with adenocarcinoma of the esophagus and a history of chronic anemia died due to bone marrow failure."

On this news, Adaptimmune's stock price fell $0.12 per share, or 5.88%, to close at $1.92 per share on September 9, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137595

info